The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Jan 21

PMID 36672305

Authors

Alessio Rizzo

Manuela Racca

Sara DallArmellina

Pasquale Rescigno

Giuseppe Luigi Banna

Domenico Albano

Francesco Dondi

Francesco Bertagna

Salvatore Annunziata

Giorgio Treglia

Affiliations

Soon will be listed here.

Abstract

Background: Recent articles proposed the employment of positron emission tomography/computed tomography (PET/CT) with prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals in clear cell renal cell carcinoma (ccRCC).

Methods: The authors performed a comprehensive literature search of studies on the performance of PET/CT with PSMA-targeting radiopharmaceuticals in ccRCC. Original articles concerning this imaging examination were included in newly diagnosed ccRCC patients and ccRCC patients with disease recurrence.

Results: A total of sixteen papers concerning the diagnostic performance of PSMA-targeted PET/CT in ccRCC (331 patients) were included in this systematic review. The included articles demonstrated an excellent detection rate of PSMA-targeting PET/CT in ccRCC.

Conclusions: PSMA-targeted PET/CT seems promising in detecting ccRCC lesions as well as in discriminating the presence of aggressive phenotypes. Prospective multicentric studies are warranted to strengthen the role of PSMA-targeting PET/CT in ccRCC.

Citing Articles

Targeting Surface Markers in Anaplastic Thyroid Cancer: Future Directions in Ligand-bound Therapy.

Pakkianathan J, Chan S, Cruz J, Ewan K, Simental A, Khan S J Endocr Soc. 2025; 9(4):bvaf035.

PMID: 40071065 PMC: 11893542. DOI: 10.1210/jendso/bvaf035.

Theranostics in Renal Cell Carcinoma-A Step Towards New Opportunities or a Dead End-A Systematic Review.

Jozwik-Plebanek K, Saracyn M, Kolodziej M, Kaminska O, Durma A, Madra W Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770563 PMC: 11678666. DOI: 10.3390/ph17121721.

The Role of 11C-Methionine PET Imaging for the Evaluation of Lymphomas: A Systematic Review.

Dondi F, Gazzilli M, Vigano G, Pisani A, Ferrari C, Rubini G Hematol Rep. 2024; 16(4):752-768.

PMID: 39728002 PMC: 11675220. DOI: 10.3390/hematolrep16040072.

Diagnostic Performance of Prostate-Specific Membrane Antigen-Targeted Positron Emission Tomography in Patients Diagnosed with Different Types of Breast Cancer: A Systematic Review.

Rizzo A, Albano D, Marchio C, Dondi F, Racca M, Bertagna F Int J Mol Sci. 2024; 25(21).

PMID: 39518965 PMC: 11546718. DOI: 10.3390/ijms252111413.

Imaging in Renal Cell Carcinoma Detection.

Woon D, Qin S, Al-Khanaty A, Perera M, Lawrentschuk N Diagnostics (Basel). 2024; 14(18).

PMID: 39335784 PMC: 11431198. DOI: 10.3390/diagnostics14182105.

References

Liu Y, Ghesani N, Zuckier L . Physiology and pathophysiology of incidental findings detected on FDG-PET scintigraphy. Semin Nucl Med. 2010; 40(4):294-315. DOI: 10.1053/j.semnuclmed.2010.02.002. View

Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S . European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022; 82(4):399-410. DOI: 10.1016/j.eururo.2022.03.006. View

Gao J, Xu Q, Fu Y, He K, Zhang C, Zhang Q . Comprehensive evaluation of Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2020; 48(2):561-569. DOI: 10.1007/s00259-020-04916-6. View

Urso L, Castello A, Rocca G, Lancia F, Panareo S, Cittanti C . Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives. J Cancer Res Clin Oncol. 2022; 148(6):1299-1311. PMC: 9114025. DOI: 10.1007/s00432-022-03958-7. View

Meyer A, Carducci M, Denmeade S, Markowski M, Pomper M, Pierorazio P . Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted F-DCFPyL PET/CT. Ann Nucl Med. 2019; 33(8):617-623. PMC: 9774684. DOI: 10.1007/s12149-019-01371-8. View

Hekman M, Rijpkema M, Aarntzen E, Mulder S, Langenhuijsen J, Oosterwijk E . Positron Emission Tomography/Computed Tomography with Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. Eur Urol. 2018; 74(3):257-260. DOI: 10.1016/j.eururo.2018.04.026. View

Moore L, Nickerson M, Brennan P, Toro J, Jaeger E, Rinsky J . Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet. 2011; 7(10):e1002312. PMC: 3192834. DOI: 10.1371/journal.pgen.1002312. View

Liu Y, Wang G, Yu H, Wu Y, Lin M, Gao J . Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients. Nucl Med Commun. 2020; 41(12):1299-1305. DOI: 10.1097/MNM.0000000000001285. View

Andreucci E, Peppicelli S, Carta F, Brisotto G, Biscontin E, Ruzzolini J . Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis. J Mol Med (Berl). 2017; 95(12):1341-1353. DOI: 10.1007/s00109-017-1590-9. View

10.

Maranchie J, Afonso A, Albert P, Kalyandrug S, Phillips J, Zhou S . Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat. 2003; 23(1):40-6. DOI: 10.1002/humu.10302. View

11.

Chen Y, Lisok A, Chatterjee S, Wharram B, Pullambhatla M, Wang Y . [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance. Bioconjug Chem. 2016; 27(7):1655-62. PMC: 5516890. DOI: 10.1021/acs.bioconjchem.6b00195. View

12.

Sengupta S, Lohse C, Leibovich B, Frank I, Thompson R, Webster W . Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005; 104(3):511-20. DOI: 10.1002/cncr.21206. View

13.

Low G, Huang G, Fu W, Moloo Z, Girgis S . Review of renal cell carcinoma and its common subtypes in radiology. World J Radiol. 2016; 8(5):484-500. PMC: 4882405. DOI: 10.4329/wjr.v8.i5.484. View

14.

Khor L, Dhakal H, Jia X, Reynolds J, McKenney J, Rini B . Tumor Necrosis Adds Prognostically Significant Information to Grade in Clear Cell Renal Cell Carcinoma: A Study of 842 Consecutive Cases From a Single Institution. Am J Surg Pathol. 2016; 40(9):1224-31. DOI: 10.1097/PAS.0000000000000690. View

15.

Wester H, Schottelius M . PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. Semin Nucl Med. 2019; 49(4):302-312. DOI: 10.1053/j.semnuclmed.2019.02.008. View

16.

van Oostenbrugge T, Mulders P . Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab. Curr Opin Urol. 2021; 31(3):249-254. DOI: 10.1097/MOU.0000000000000872. View

17.

Li Y, Zheng R, Zhang Y, Huang C, Tian L, Liu R . Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma. Int J Cancer. 2022; 152(1):42-50. PMC: 9796964. DOI: 10.1002/ijc.34189. View

18.

Linehan W, Srinivasan R, Schmidt L . The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010; 7(5):277-85. PMC: 2929006. DOI: 10.1038/nrurol.2010.47. View

19.

Motzer R, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K . Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(1):71-90. PMC: 10191161. DOI: 10.6004/jnccn.2022.0001. View

20.

Israeli R, Powell C, Fair W, Heston W . Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993; 53(2):227-30. View